![]() |
In 2003, the Hong Kong IPO market, then as now dominated by aspiring mainland corporates, started off with a bang before tailing off sharply as news of a deadly new pathogen emerged. Severe acute respiratory syndrome, or SARS, resulted in 774 deaths, with Hong Kong and Beijing hardest hit.
For a while, the city’s capital markets all but closed down. One after the other, mainland firms delayed their Hong Kong listing plans.
Thanks for your interest in Euromoney!
To unlock this article, enter your e-mail to log in or enquire about access: